Good Distribution Practice for Active Substances Used as Starting Materials in Veterinary Medicinal Products
Commission Implementing Regulation (EU) 2021/1280 of 2 August 2021 — the GDP rules for active substances used as starting materials in veterinary medicinal products, adopted under Regulation (EU) 2019/6. Unlike its human-medicines counterpart (the 2015 guidelines), it is a directly applicable regulation: importers, distributors, and manufacturers who distribute their own veterinary active substances must run a documented quality system covering personnel, documentation, operations, complaints, returns, recalls, and self-inspection.
What this does not cover
stated in the document's own scope- Covers distribution of active substances used as starting materials in veterinary medicinal products; the manufacture of those substances is a GMP matter, not GDP.
- Applies to the veterinary chain; active substances for human medicines follow the 2015 guidelines (2015/C 95/01).
- Governs active-substance distribution; finished veterinary medicinal products are distributed under Implementing Regulation (EU) 2021/1248.
- Sets GDP obligations; authorisation and registration of veterinary medicines themselves sit in Regulation (EU) 2019/6.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Commission Implementing Regulation (EU) 2021/1280 sets good distribution practice for active substances used as starting materials in veterinary medicinal products. It requires importers and distributors of veterinary active substances — and manufacturers distributing active substances they made — to operate a documented quality system, with provisions for personnel, documentation and records giving traceability of each supply, premises and equipment, receipt, storage, and delivery operations, supplier and customer qualification, complaints, returns, recalls, and self-inspection. It is the veterinary sibling of the 2015 human-medicines API GDP guidelines, but in a stronger legal form: a directly applicable EU regulation rather than Commission guidance.
Scope & applicability
Importers and distributors of active substances used as starting materials in veterinary medicinal products in the EU, and manufacturers distributing active substances they manufactured. Finished veterinary product distribution is governed by the parallel Implementing Regulation (EU) 2021/1248.
Legal basis & how it acquires force
An implementing regulation of 2 August 2021, adopted by the European Commission under Regulation (EU) 2019/6 on veterinary medicinal products — the framework that replaced Directive 2001/82/EC and applies from 28 January 2022. As an EU regulation it is directly applicable in all Member States without transposition. It was published in the Official Journal on 3 August 2021, alongside the parallel Implementing Regulation (EU) 2021/1248 on GDP for finished veterinary medicinal products.
Document structure
| Part | Covers |
|---|---|
| Scope and definitions | The distribution activities and actors covered, including manufacturers distributing their own active substances |
| Quality system and personnel | The documented quality system, designated responsibilities, and training |
| Documentation, premises and equipment | Procedures and traceability records, and the facilities and equipment used in distribution |
| Operations | Receipt, storage, and supply of veterinary active substances, with verification of suppliers and customers |
| Complaints, returns and recalls | Handling quality complaints, returned substances, and recall execution |
| Self-inspections | Periodic internal audits of GDP compliance |
Key requirements
- Operate a documented quality system for the distribution of veterinary active substances
- Maintain records providing traceability for each supply
- Store and transport active substances under required conditions with appropriate premises and equipment
- Qualify suppliers and customers and handle complaints, returns, and recalls
- Perform self-inspections of the GDP operation
Implementation tips
- Sites distributing both human and veterinary active substances should run one quality system mapped to both instruments — the technical content is closely aligned, but the veterinary text is binding law while the human text is guidance
Revision notes
Adopted 2 August 2021 under Regulation (EU) 2019/6, which applies from 28 January 2022 as the EU's new veterinary-medicines framework.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The regulation transfers the substance of the EU's human-medicines API GDP guidelines (2015/C 95/01) into the veterinary framework created by Regulation (EU) 2019/6, applying similar measures to the veterinary domain unless veterinary-specific needs dictate otherwise. It sits in a package with Implementing Regulation (EU) 2021/1248 (GDP for finished veterinary products), and upstream of it the manufacture of veterinary active substances follows GMP principles equivalent to ICH Q7.
Impl. Reg. (EU) 2021/1280: frequently asked questions
Quick answers to common questions about Impl. Reg. (EU) 2021/1280.
Who must comply with Implementing Regulation (EU) 2021/1280?
Importers and distributors of active substances used as starting materials in veterinary medicinal products in the EU, and manufacturers that distribute active substances they manufactured. All must operate the documented GDP quality system the regulation prescribes.
How does it differ from the human API GDP guidelines?
In legal form more than technical content. The human-medicines text (2015/C 95/01) is Commission guidance interpreting Directive 2001/83/EC; the veterinary text is a directly applicable implementing regulation under Regulation (EU) 2019/6. The controls — quality system, traceability, storage, supplier and customer checks, recalls, self-inspection — are closely aligned.
When did the veterinary API GDP rules take effect?
The regulation was adopted on 2 August 2021 and operates within the veterinary-medicines framework of Regulation (EU) 2019/6, which applies from 28 January 2022.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.